A novel lncRNA (Ephemeron) is connected to known post-transcriptional and epigenetic regulators as part of an integrated machinery, which controls the timely exit from the naïve state of mouse embryonic stem cells.
GDC-0810 is a novel, orally bioavailable SERD that exhibits robust pre-clinical activity in models of ER+ breast cancer, including models of tamoxifen resistance, and those that express the ERα mutations, ER.Y537S and ER.D538G.
The IGF2 mRNA binding protein-2/IMP2, overexpressed in many common cancers, drives cancer cell proliferation by increasing the abundance of IGF2 and the oncogene HMGA1, which controls a network of effectors that enhance IGF2 action.
Building on previous work (Muir et al., 2014), we validate the utility of a screen for new protein kinase substrates and define the underlying molecular basis of a new mechanism for responding to hypertonic conditions.
Building on previous work (Booth et al, 2014), we show how two mitotic phosphatases are formed, how they are regulated by opposing kinases during the cell cycle and reveal a novel opportunity for the development of cancer therapeutics.
Genetic and biochemical evidence shows that the basal transcription machinery of muscle cells invariably relies on TBP/TFIID because TBP2 is not expressed in muscle cells, and thus resolves a longstanding issue raised by previous conflicting data.